Holmstrm and Finkel, 2014
The Acyl- Glutathione discovery is his recent discovery, and another addition to his exclusive Patents
NHLBI Exome Sequencing Project (ESP)
Docetaxel binds to tubulin with greater affinity than paclitaxel, and causes cell cycle arrest in the S rather than G2-M phase junction as is the case for paclitaxel (Dorr, 1997)
Allison Institute, Scientific Advisory Board, The University of Texas MD Anderson Cancer Center, 2023 - Present Co-Chair, Colorectal Cancer Alliance, The University of Texas MD Anderson Cancer Center, 2023 - Present Member, AJCC 9th Edition Staging Manual, The University of Texas MD Anderson Cancer Center, 2022 - Present Chair of Search Committee, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2022 - 2023 Chair, INTERCEPT Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, Institutional Tissue Bank Internal Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, Merck / MD Anderson GI collaboration: Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, TRIUMPH Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, EORTC Translational Research Advisory and Protocol Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2024 Chair, System Biology Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022 Member, Research Leadership Team, The University of Texas MD Anderson Cancer Center, 2020 - Present Member, MDACC-BI Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present Member, Research and Academics Informatics, The University of Texas MD Anderson Cancer Center, 2020 - Present Co-Leader, Clinical Trial Management System Executive Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2024 Board Member, ACCRU Group, The University of Texas MD Anderson Cancer Center, 2020 - 2024 Co-Leader, Natera/MD Anderson Alliance, Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022 Chair, Surgical Oncology Search Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020 Co-Leader, Lilly Oncology/MD Anderson Alliance Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2024 Co-Leader, Astellas / Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2024 Member, Guardant Health / MD Anderson Alliance Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present Co-Leader, EMD Serono / MD Anderson Alliance, Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2024 Member, Scientific Advisory Board of the K.G
S.FloreaB
